Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 2/20 | 0.33 |
| ▸ | HRAS | P01112 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23728911 | 0.93 | MEN1 (0.33) | TOP1HRASESR1ESR2KDM4E | |
| SCHEMBL23728949 | 0.93 | MEN1 (0.33) | TOP1HRASESR1ESR2KDM4E | |
| SCHEMBL23728922 | 0.89 | HDAC1 (0.32) | TOP1HRASESR1ESR2KDM4E | |
| SCHEMBL23728900 | 0.88 | MC4R (0.35) | TOP1HRASESR1ESR2KDM4E | |
| SCHEMBL23728968 | 0.85 | — | — | |
| SCHEMBL23728934 | 0.84 | KDM4E (0.33) | KDM4EMAPT | |
| SCHEMBL23728958 | 0.84 | KDM4E (0.33) | KDM4EMAPT | |
| SCHEMBL23728952 | 0.84 | P2RX3 (0.35) | TOP1HRASESR1ESR2KDM4E | |
| SCHEMBL23728901 | 0.83 | TOP1 (0.33) | TOP1HRASESR1ESR2KDM4E | |
| SCHEMBL23728955 | 0.82 | TOP1 (0.35) | TOP1HRASESR1ESR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100404-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |